Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Read More →
Ribociclib 200 mg
Everest Pharmaceuticals Ltd. About the Manufacturer
Company Name: Everest Pharmaceuticals Ltd.
Industry: Pharmaceutical Manufacturing
Country: Bangladesh
Business Activities: Manufacturing, marketing, and distribution of pharmaceutical products
Product Areas: Includes specialized and general pharmaceutical medicines
Strength: 200 mg per tablet
Dosage Form: Film-coated oral tablet, according to available Ribokis product information.
Drug Class: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor
Therapeutic Category: Antineoplastic / anticancer medicine
Quality Focus: Product manufacturing and quality-control processes are intended to support medicine quality, safety, and regulatory compliance. For product-specific information, it is important to check the official packaging, product insert, batch details, and manufacturer information, as formulations and regulatory status may vary by product and market.
Head Office: Everest Pharmaceuticals Ltd. is located at Rahman’s Regnum Centre (10th & 11th floor), 191/1 Tejgaon Commercial Area, Dhaka-1208, Bangladesh.
Manufacturing Plant: Everest Pharmaceuticals Limited B-33, 45 & 46, BSCIC, Kanchpur, Narayanganj–1430, Bangladesh. Ribokis 200 mg (Ribociclib) is manufactured by Everest Pharmaceuticals Ltd., a pharmaceutical company based in Bangladesh.
Reference Product
KISQALI (ribociclib)
KISQALI was developed by Novartis under a research collaboration involving Astex Pharmaceuticals and received its initial U.S. approval in 2017.
What Is Ribokis 200 mg?
Ribokis 200 mg contains ribociclib, an oral targeted anticancer medicine belonging to the CDK4/6 inhibitor class.
Ribociclib works by inhibiting CDK4 and CDK6, proteins involved in regulating progression through the cell cycle. By interfering with these proteins, ribociclib can slow the proliferation of susceptible cancer cells.
It is primarily used in treatment plans for certain hormone receptor-positive (HR-positive), HER2-negative breast cancers and is generally administered together with appropriate endocrine therapy.
The exact indication depends on the patient’s disease stage, menopausal status, previous treatment, risk of recurrence, and the applicable regulatory approval.
What Is Ribociclib Used For?
Current U.S. labeling includes ribociclib for specified HR-positive, HER2-negative breast cancer populations.
These include:
- Certain patients with HR-positive, HER2-negative early breast cancer
- Certain patients with HR-positive, HER2-negative advanced breast cancer
- Certain patients with HR-positive, HER2-negative metastatic breast cancer
For advanced or metastatic disease, ribociclib may be used with:
- An aromatase inhibitor as initial endocrine-based therapy
- Fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in appropriate patients
The current U.S. label should be consulted for the exact eligibility criteria and treatment combinations.
How Does Ribociclib Work?
Ribociclib selectively inhibits cyclin-dependent kinases 4 and 6.
CDK4 and CDK6 participate in cell-cycle regulation. When these enzymes become activated, they help cells progress through the cell cycle and divide.
Ribociclib inhibits CDK4/6 activity, which can interfere with progression of susceptible cells through the cell cycle.
In simple terms:
Ribociclib → inhibits CDK4/CDK6 → interferes with cell-cycle progression → helps slow proliferation of susceptible breast-cancer cells.
This mechanism is different from conventional cytotoxic chemotherapy, so ribociclib is generally described as a targeted anticancer therapy.
Ribociclib 200 mg Dosage
The 200 mg tablet is a strength, not necessarily the complete daily dose.
Current U.S. KISQALI labeling uses 200 mg tablets to construct different treatment doses. For example:
| Treatment setting | Recommended starting dose |
|---|---|
| Selected early breast cancer | 400 mg once daily |
| Advanced/metastatic breast cancer | 600 mg once daily |
For early breast cancer, the 400 mg dose corresponds to two 200 mg tablets once daily.
For advanced or metastatic breast cancer, the 600 mg dose corresponds to three 200 mg tablets once daily.
These doses are prescribing-information regimens and not an instruction for an individual patient. The treating oncologist determines the appropriate regimen.
How and When to Take Ribociclib
Ribociclib is taken once daily according to the prescribed treatment cycle.
The current U.S. regimen generally consists of:
21 consecutive days of treatment followed by 7 days without treatment, making one 28-day cycle.
Patients should:
- Take the medicine at approximately the same time each day.
- Swallow tablets whole.
- Do not chew, crush, or split tablets.
- Follow the prescribed treatment schedule.
- Never change the dose without medical advice.
Should Ribociclib Be Taken With Food?
Ribociclib may be taken with or without food.
Patients should try to take it consistently according to their prescribed schedule.
What If a Dose Is Missed?
If a patient misses a dose, the current U.S. prescribing information advises taking the next prescribed dose at the usual time rather than taking an additional dose.
If vomiting occurs after taking ribociclib, another dose should not be taken that same day unless specifically instructed by the healthcare professional.
Common Side Effects
Common adverse reactions associated with ribociclib include:
- Neutropenia
- Nausea
- Fatigue
- Infections
- Diarrhea
- Leukopenia
- Vomiting
- Alopecia
- Headache
- Constipation
- Rash
- Cough
The exact frequency and severity can vary according to the treatment setting and whether ribociclib is being used with another anticancer medicine.
Serious Side Effects and Important Risks
Ribociclib can cause potentially serious adverse reactions, including:
Neutropenia
Ribociclib can significantly reduce neutrophil counts and increase the risk of infection.
A patient should promptly contact their healthcare provider if they develop fever or other signs of infection.
QT Interval Prolongation
Ribociclib can prolong the QT interval on an ECG, potentially increasing the risk of serious cardiac rhythm abnormalities.
Hepatotoxicity
Ribociclib can cause liver toxicity, making liver function monitoring important.
Interstitial Lung Disease / Pneumonitis
Ribociclib can cause ILD or pneumonitis, including severe or potentially fatal cases.
New or worsening:
- Cough
- Shortness of breath
- Difficulty breathing
should be medically evaluated promptly.
Severe Skin Reactions
Serious cutaneous reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS, have been reported.
Embryo-Fetal Toxicity
Ribociclib may cause fetal harm and requires appropriate pregnancy precautions.
Who Should Avoid Ribociclib?
Ribociclib should not be used by people with a known hypersensitivity to ribociclib or any component of the product.
Treatment also requires particular caution and medical assessment in patients with:
- Significant cardiac problems
- Existing QT prolongation
- Electrolyte abnormalities
- Liver impairment
- Previous serious drug reactions
- Conditions increasing infection risk
- Significant lung disease
- Pregnancy or potential pregnancy
- Other medicines that interact with ribociclib
The prescribing oncologist should review the patient’s complete medical history before treatment.
Drug Interactions
Ribociclib has clinically important drug interactions.
Strong CYP3A inhibitors
Strong CYP3A inhibitors can increase ribociclib exposure and may increase toxicity, including QT prolongation.
Examples of strong CYP3A inhibitors include certain antifungal medicines and antiviral medicines.
The current U.S. label recommends avoiding strong CYP3A inhibitors when possible. If unavoidable, dose modification is required according to the treatment indication.
Strong CYP3A inducers
Strong CYP3A inducers can decrease ribociclib concentrations and potentially reduce its effectiveness.
They should generally be avoided when alternative medicines are available.
QT-prolonging medicines
Patients should avoid medicines known to prolong the QT interval when possible because combining them with ribociclib can increase cardiac risk.
Patients should provide their doctor and pharmacist with a complete list of:
- Prescription medicines
- OTC medicines
- Vitamins
- Herbal products
- Supplements
before starting treatment.
Food and Lifestyle Considerations
Ribociclib can be taken with or without food.
Patients should discuss dietary supplements, herbal medicines, and other non-prescription products with their healthcare professional because some substances can affect drug-metabolizing enzymes.
Because ribociclib treatment can affect blood counts, liver function, and cardiac electrical activity, patients should follow their oncology team’s monitoring schedule carefully.
Monitoring During Ribociclib Treatment
Treatment generally requires regular monitoring.
Depending on the treatment setting, monitoring can include:
- Complete blood counts (CBC)
- Liver-function tests
- Electrolytes
- ECG
- Assessment for infection
- Assessment for respiratory symptoms
- Review of concomitant medicines
Dose interruption or reduction may be necessary when clinically significant toxicity develops.
Pregnancy and Breastfeeding
Ribociclib can cause embryo-fetal toxicity.
Women who can become pregnant should discuss effective contraception with their healthcare professional. Current U.S. labeling advises contraception during treatment and for at least 3 weeks after the final dose.
Current U.S. labeling also advises patients not to breastfeed during treatment and for at least 3 weeks after the final dose.
Storage
Storage conditions should be checked against the actual Ribokis package insert and manufacturer documentation.
Patients should:
- Keep the medicine in its original packaging unless instructed otherwise.
- Keep it away from excessive heat and moisture.
- Keep it out of the reach of children.
- Check the expiry date before use.
- Do not use tablets from damaged or questionable packaging.
Because product-specific storage instructions for Ribokis should come from Everest Pharmaceuticals’ official documentation, the website should avoid inventing a temperature or storage specification unless it is verified.
Ribokis 200 mg Product Information
| Product information | Details |
|---|---|
| Brand name | Ribokis |
| Active ingredient | Ribociclib |
| Strength | 200 mg |
| Dosage form | Film-coated tablet* |
| Route | Oral |
| Drug class | CDK4/6 inhibitor |
| Therapeutic category | Antineoplastic |
| Main treatment area | Breast cancer |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Country | Bangladesh |
| Reference product | KISQALI |
| Reference-product developer | Novartis / Astex Pharmaceuticals collaboration |
| Prescription status | Prescription medicine |
*Product documentation should be checked for the exact Ribokis presentation. Available product listings identify Ribokis 200 mg as a tablet.
Ribokis vs KISQALI
Ribokis and KISQALI both contain ribociclib, but they should not automatically be described as identical products.
They may differ in:
- Manufacturer
- Manufacturing site
- Excipients
- Packaging
- Product authorization
- Marketing authorization holder
- Distribution channel
- Country-specific registration
Therefore, the safest wording for the website is:
Ribokis 200 mg contains ribociclib. KISQALI is the established reference ribociclib product. The two products should not be considered identical solely because they contain the same active ingredient.
This distinction is particularly important for a pharmaceutical-information website.
Everest Pharmaceuticals Ltd. Product Verification Process
To verify the authenticity of an Everest Pharmaceuticals product, follow the verification process below:
Scan the QR Code: Scan the QR code printed on the product box. The QR code will direct you to the official product verification page.
Open the Box: After accessing the verification page, open the product box and locate the verification code printed on the bottle.
Submit the Verification Code: Enter the verification code from the bottle on the verification page and submit it to check the product’s authenticity.
Verification Success: If the verification is successful, the product is confirmed as legitimate.
Verification Error: If the system displays a verification error, the product may be counterfeit or unauthorized. Do not use the product until its authenticity has been confirmed through an appropriate official channel.
Counterfeit Products: If a product is confirmed to be fake, do not use or distribute it. Report the suspected counterfeit product and supplier to the appropriate regulatory authorities, such as the Directorate General of Drug Administration (DGDA) in World, and take appropriate legal action against the supplier through the relevant authorities.
Important: Always purchase medicines from licensed pharmacies or authorized suppliers and verify suspicious products before use.
Important Medical Disclaimer
Ribokis 200 mg is a prescription anticancer medicine. The information above is educational and should not be used to diagnose a condition or determine an individual patient’s treatment.
The correct ribociclib dose depends on the indication, treatment combination, patient characteristics, laboratory results, tolerability, and applicable prescribing information.
Patients should not start, stop, increase, decrease, or modify ribociclib treatment without the direction of their treating oncology professional.
The supplied website material should also retain a clear distinction between Ribokis-specific product facts and information taken from the KISQALI reference product labeling.
Latest News
FAQs
Yes. Tiredness or fatigue can occur during ribociclib treatment. It may range from mild to more noticeable and can sometimes be related to the medicine itself, the underlying cancer, anemia, or other treatments being taken at the same time. Tell your healthcare professional if fatigue becomes persistent, severe, or interferes with normal daily activities. Your doctor can assess possible causes and determine whether additional tests or treatment adjustments are appropriate.
Ribociclib may cause digestive side effects such as nausea, vomiting, diarrhea, constipation, or reduced appetite in some patients. If these symptoms occur, keep your healthcare team informed, particularly if they are persistent or severe. Your doctor or pharmacist may recommend appropriate supportive measures. Do not start an anti-nausea medicine, antidiarrheal product, herbal preparation, or other treatment without checking with your healthcare professional.
Changes in hair or hair thinning may occur in some people receiving anticancer treatment, although the pattern and severity can vary. Ribociclib is a targeted CDK4/6 inhibitor rather than traditional cytotoxic chemotherapy, so its side-effect profile is different from many conventional chemotherapy medicines. If you notice significant hair loss, thinning, or changes in your hair or scalp, discuss this with your healthcare professional.
Yes. Ribociclib can reduce certain blood cell counts, particularly neutrophils, which are white blood cells that help the body fight infections. It may also affect other blood cell types in some patients. This is one reason regular blood tests are an important part of treatment. Your healthcare professional will review your blood counts and determine whether treatment can continue as planned or whether additional monitoring or treatment changes are needed.
Yes. Ribociclib can interact with certain prescription medicines, over-the-counter products, supplements, and herbal preparations. Some interactions can change the amount of ribociclib in the body, while others may increase the risk of side effects or affect heart rhythm. Before starting treatment, provide your doctor and pharmacist with a complete list of medicines, vitamins, supplements, and herbal products you use.
Yes. Before starting ribociclib, tell your healthcare professional about your complete medical history. This is particularly important if you have or previously had liver problems, heart rhythm problems, an abnormal electrocardiogram, electrolyte abnormalities, or other significant medical conditions. Also provide information about all medicines and supplements you use.
Ribociclib can affect the electrical activity of the heart and may prolong the QT interval on an electrocardiogram, or ECG. For this reason, ECG monitoring may be performed before and during treatment according to applicable prescribing information and your clinical situation. Your healthcare team may also monitor electrolyte levels. Seek prompt medical attention if you experience fainting, significant dizziness, or an abnormal or rapid heartbeat.
Ribociclib can cause changes in liver enzymes and, in some patients, more significant liver-related toxicity. Liver function tests may therefore be monitored during treatment. Contact your healthcare professional if you develop symptoms such as yellowing of the skin or eyes, unusually dark urine, persistent nausea, loss of appetite, or pain in the upper right area of the abdomen.
Tell your surgeon, oncologist, anesthesiologist, and other relevant healthcare professionals that you are taking ribociclib. Your medical team may need to review your blood counts, liver function, heart rhythm, other medicines, and the planned procedure. Do not stop ribociclib on your own before an operation. Your oncology team should determine whether treatment needs to be adjusted or temporarily interrupted.
The length of ribociclib treatment varies from person to person and depends on factors such as the treatment setting, response to treatment, tolerability, other medicines being used, and your doctor's treatment plan. Your oncologist will monitor your condition and determine how long treatment should continue. Do not stop treatment simply because you feel better. Follow the treatment plan provided by your healthcare professional.